中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
13期
1936-1939,后插3
,共5页
丁体龙%马勇%王勇%代雪枫
丁體龍%馬勇%王勇%代雪楓
정체룡%마용%왕용%대설풍
青蒿琥酯%间质干细胞移植%肝硬化
青蒿琥酯%間質榦細胞移植%肝硬化
청호호지%간질간세포이식%간경화
Artesunate%Mesenchymal stem cell transplantation%Liver cirrhosis
目的 研究骨髓间充质干细胞(BMSCs)联合青蒿琥酯(Art)对肝纤维化大鼠模型的治疗效果.方法 120只SD大鼠,随机抽取20只作健康对照组,另随机取10只处死后取骨髓作BMSCs培养,剩下的90只采用四氯化碳(CCl4)腹腔注射构建大鼠肝纤维化模型,10周后随机处死10只,取肝组织作病理观察以验证肝纤维化模型制作成功.其余80只按数字表法随机分为模型组、Art治疗组、BMSCs移植组和联合治疗组,每组20只.Masson染色观察肝组织纤维化改变,RT-PCR法检测肝组织α-平滑肌肌动蛋白(α-SMA) mRNA、TGF-β1 mRNA的表达,采用酶消化法检测羟脯氨酸(Hyp)含量,血清TNF-α、TGF-β1检测采用酶免法,血清肝纤维化指标检测采用化学发光法,肝功能指标采用生化法检测.结果 联合治疗组肝功能指标明显优于其他组,联合治疗组白蛋白(ALB)为(29.13 ±3.48) g/L,显著高于Art治疗组[(26.31±2.42) g/L]、BMSCs移植组[(24.35 ±3.12)g/L]和模型组[(20.14 ±2.86)g/L],差异均有统计学意义(q=6.27 ～ 19.01,均P＜0.05);联合治疗组肝纤维化指标显著低于其他组,联合治疗组Hyp为(1.03 ±0.16) μg/L,显著低于Art治疗组[(1.56±0.19) μg/L]、BMSCs移植组[(1.45±0.24) μg/L]和模型组[(3.57 ±0.91)μg/L],差异均有统计学意义(q =20.47 ～27.70,均P＜0.05);联合治疗组肝组织TGF-β1 mRNA表达强度明显低于其它组,联合治疗组肝组织电泳条带灰度值占对照条带灰度值百分比为(20.16 ±5.21),显著低于Art治疗组(58.15±9.16)、BMSCs移植组(46.31±6.82)和模型组(97.08±14.23),差异均有统计学意义(q=20.35 ～44.93,均P ＜0.05).结论 BMSCs联合Art在肝纤维化治疗过程中有较好的协同作用.
目的 研究骨髓間充質榦細胞(BMSCs)聯閤青蒿琥酯(Art)對肝纖維化大鼠模型的治療效果.方法 120隻SD大鼠,隨機抽取20隻作健康對照組,另隨機取10隻處死後取骨髓作BMSCs培養,剩下的90隻採用四氯化碳(CCl4)腹腔註射構建大鼠肝纖維化模型,10週後隨機處死10隻,取肝組織作病理觀察以驗證肝纖維化模型製作成功.其餘80隻按數字錶法隨機分為模型組、Art治療組、BMSCs移植組和聯閤治療組,每組20隻.Masson染色觀察肝組織纖維化改變,RT-PCR法檢測肝組織α-平滑肌肌動蛋白(α-SMA) mRNA、TGF-β1 mRNA的錶達,採用酶消化法檢測羥脯氨痠(Hyp)含量,血清TNF-α、TGF-β1檢測採用酶免法,血清肝纖維化指標檢測採用化學髮光法,肝功能指標採用生化法檢測.結果 聯閤治療組肝功能指標明顯優于其他組,聯閤治療組白蛋白(ALB)為(29.13 ±3.48) g/L,顯著高于Art治療組[(26.31±2.42) g/L]、BMSCs移植組[(24.35 ±3.12)g/L]和模型組[(20.14 ±2.86)g/L],差異均有統計學意義(q=6.27 ～ 19.01,均P＜0.05);聯閤治療組肝纖維化指標顯著低于其他組,聯閤治療組Hyp為(1.03 ±0.16) μg/L,顯著低于Art治療組[(1.56±0.19) μg/L]、BMSCs移植組[(1.45±0.24) μg/L]和模型組[(3.57 ±0.91)μg/L],差異均有統計學意義(q =20.47 ～27.70,均P＜0.05);聯閤治療組肝組織TGF-β1 mRNA錶達彊度明顯低于其它組,聯閤治療組肝組織電泳條帶灰度值佔對照條帶灰度值百分比為(20.16 ±5.21),顯著低于Art治療組(58.15±9.16)、BMSCs移植組(46.31±6.82)和模型組(97.08±14.23),差異均有統計學意義(q=20.35 ～44.93,均P ＜0.05).結論 BMSCs聯閤Art在肝纖維化治療過程中有較好的協同作用.
목적 연구골수간충질간세포(BMSCs)연합청호호지(Art)대간섬유화대서모형적치료효과.방법 120지SD대서,수궤추취20지작건강대조조,령수궤취10지처사후취골수작BMSCs배양,잉하적90지채용사록화탄(CCl4)복강주사구건대서간섬유화모형,10주후수궤처사10지,취간조직작병리관찰이험증간섬유화모형제작성공.기여80지안수자표법수궤분위모형조、Art치료조、BMSCs이식조화연합치료조,매조20지.Masson염색관찰간조직섬유화개변,RT-PCR법검측간조직α-평활기기동단백(α-SMA) mRNA、TGF-β1 mRNA적표체,채용매소화법검측간포안산(Hyp)함량,혈청TNF-α、TGF-β1검측채용매면법,혈청간섬유화지표검측채용화학발광법,간공능지표채용생화법검측.결과 연합치료조간공능지표명현우우기타조,연합치료조백단백(ALB)위(29.13 ±3.48) g/L,현저고우Art치료조[(26.31±2.42) g/L]、BMSCs이식조[(24.35 ±3.12)g/L]화모형조[(20.14 ±2.86)g/L],차이균유통계학의의(q=6.27 ～ 19.01,균P＜0.05);연합치료조간섬유화지표현저저우기타조,연합치료조Hyp위(1.03 ±0.16) μg/L,현저저우Art치료조[(1.56±0.19) μg/L]、BMSCs이식조[(1.45±0.24) μg/L]화모형조[(3.57 ±0.91)μg/L],차이균유통계학의의(q =20.47 ～27.70,균P＜0.05);연합치료조간조직TGF-β1 mRNA표체강도명현저우기타조,연합치료조간조직전영조대회도치점대조조대회도치백분비위(20.16 ±5.21),현저저우Art치료조(58.15±9.16)、BMSCs이식조(46.31±6.82)화모형조(97.08±14.23),차이균유통계학의의(q=20.35 ～44.93,균P ＜0.05).결론 BMSCs연합Art재간섬유화치료과정중유교호적협동작용.
Objective To study the effects of bone marrow mesenchymal stem cells(BMSCs) transplantation combined with artesunate(Art) on rat model of liver fibrosis.Methods 20 rats from 120 SD rats were selected randomly as normal control group.10 rats from those were executed and extracted marrow to culture BMSCs.The other 90 rats were injected intraperitoneally with CCl4 to make liver fibrosis rat models.10 rats from the 90 rats were selected randomly to ensure the liver fibrosis model was made successfully after 10 weeks.Then,the rest 80 rats were divided randomly into 4 groups:model group,Art treated group,BMSCs transplantation group and Art + BMSCs transplantation group.Fibrous degeneration of the hepatic tissue was detected by Masson stain.The mRNA expression of α-SMA,TGF-β1 in liver were detected by RT-PCR.The hydroxyproline(Hyp) level in liver was detected by enzyme digestion method.Serum TNF-αand TGF-β1 were detected by ELISA.Serum hepatic fibrosis parameters were detected by chemiluminescence and serum liver functional parameters were detected by biochemistry method.Results Liver functional parameters of Art + BMSCs transplantation group were better than those of the other groups.ALB in Art + BMSCs transplantation group was (29.13 ± 3.48) g/L,which was significantly higher than (26.31 ± 2.42) g/L in Art treated group (24.35 ±3.12)g/L in BMSCs transplantation group and (20.14 ±2.86) g/L in model group.There were significant differences among the 4 groups(q =6.27 ～ 19.01,all P ＜ 0.05).Liver fibrosis parameters of Art + BMSCs transplantation group were better than other groups.Hyp in Art + BMSCs transplantation group was (1.03 ±0.16) μg/L,which was significantly lower than (1.56 ± 0.19) μg/L in Art treated group,(1.45 ± 0.24) μg/L in the BMSCs transplantation group and (3.57 ±0.91) μg/L in the model group.There were significant differences among the 4 groups (q =20.47 ～ 27.70,all P ＜ 0.05).The expression of TGF-β1 mRNA of Art + BMSCs transplantation group was lower than other groups.The index of TGF-β1 mRNA expression in Art + BMSCs transplantation group was (20.16 ± 5.21),which was lower than (58.15 ±9.16) in Art treated group,(46.31 ±6.82) in the BMSCs transplantation group and (97.08 ± 14.23) in the model group.There were significant differences among the 4 groups (q =20.35 ～ 44.93,all P ＜ 0.05).Conclusion There're synergistic effects between Art and BMSCs in the treatment of liver fibrosis.
